Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse - Full Text View

Sponsored by:	Ethicon, Inc.
Information provided by:	Ethicon, Inc.
ClinicalTrials.gov Identifier:	NCT00833001

Purpose

The purpose of this study is to evaluate the clinical performance of the PROLIFT system with a new lighter-weight mesh in repair of vaginal prolapse.

Condition	Intervention	Phase
Cystocele Rectocele Enterocele	Device: GYNECARE PROLIFT+M* Pelvic Floor Repair System	Phase II Phase III

MedlinePlus related topics: Bladder Diseases Pelvic Support Problems

Drug Information available for: Poliglecaprone 25

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	A Prospective, Multi-Center Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse

Further study details as provided by Ethicon, Inc.:

Primary Outcome Measures:

Pelvic Organ Prolapse Quantification (POP-Q) score [ Time Frame: 12 months post-procedure ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Summary of treated compartment ICS POP-Q stage [ Time Frame: 3, 12, 24 and 36 months ] [ Designated as safety issue: No ]
Proportion of subjects with the leading edge within the hymen and without further re-intervention for POP [ Time Frame: 12, 24 and 36 months ] [ Designated as safety issue: No ]
Incidence of de novo prolapse (a post-operative prolapse)only in the untreated compartment, provided there was no pre-operative defect in that compartment [ Time Frame: Procedure to 36 months ] [ Designated as safety issue: No ]
Mean scores and change from baseline in PFDI-20 scores, including sub scores (POPDI, CRADI and UDI [ Time Frame: 3, 12, 24 and 36 months ] [ Designated as safety issue: No ]
Mean scores and change from baseline in PFIQ-7, including sub-scores (POPIQ, CRAIQ and UIQ). [ Time Frame: 3, 12, 24 and 36 months ] [ Designated as safety issue: No ]
Days to return to normal activities (walking, driving, work, household activities and sexual intercourse) [ Time Frame: 1, 3, and 12 months ] [ Designated as safety issue: No ]
Assessment of sexual function using PISQ-12 (mean scores and change from baseline) in subjects sexually active at baseline [ Time Frame: 12, 24 and 36 months ] [ Designated as safety issue: No ]
Incidence of new onset dyspareunia, resolution or continuance of pre-existing dyspareunia [ Time Frame: Baseline to 36 months ] [ Designated as safety issue: Yes ]
Adverse Events [ Time Frame: Procedure to 36 months ] [ Designated as safety issue: Yes ]
Determination of any exposures/erosions including location [ Time Frame: Procedure to 36 months ] [ Designated as safety issue: Yes ]
Summary of International Continence Society (ICS) Stages [ Time Frame: 3, 24, and 36 months ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	126
Study Start Date:	April 2008
Estimated Study Completion Date:	December 2011
Estimated Primary Completion Date:	November 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 GYNECARE PROLIFT+M* Pelvic Floor Repair System	Device: GYNECARE PROLIFT+M* Pelvic Floor Repair System Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber

Detailed Description:

Vaginal prolapse (a feeling of bulge in the vagina) may cause some distressing symptoms such as loss of control of the bowel or bladder, and may also cause problems with women's sex life. There are a number of different surgical procedures which are used to repair prolapse. Sometimes a mesh is placed in the pelvis to support the weakened tissues. There is a lot of research going on to find the most suitable type of mesh to repair vaginal prolapse. The GYNECARE PROLIFT + M* Pelvic Floor Repair system is similar to a mesh already used for this procedure called ULTRAPRO*, but is lighter in weight. Currently, ULTRAPRO* is only approved for use in hernia repair and is not licensed for gynecological procedures. This study will be the first clinical investigation of this mesh in vaginal prolapse.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Women over 18 with symptomatic pelvic organ prolapse of ICS POP-Q Stage III or IV, suitable for surgical repair.

Criteria

Inclusion Criteria:

Candidates with symptomatic pelvic organ prolapse of ICS POP-Q Stage III or IV, suitable for surgical repair. Perineal repair, vaginal hysterectomy and/or mid urethral sling procedures for incontinence may be performed concurrently.
Age > or = 18 years.
Agrees to participate in the study, including completion of all study-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.

Exclusion Criteria:

Additional surgical intervention for POP repair concurrent to the Gynecare Prolift+M procedure (e.g. paravaginal repair, sacrocolpopexy, colporrhaphy in a non-Gynecare Prolift+M treated compartment).
Previous repair of pelvic organ prolapse involving insertion of mesh.
Previous hysterectomy within 6 months of scheduled surgery.
Experimental drug or experimental medical device within 3 months prior to the planned procedure.
Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
History of any pelvic radiation therapy.
History of chemotherapy within 6 months of the planned procedure.
Systemic disease known to affect bladder or bowel function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvodynia).
Nursing or pregnant or intends future pregnancy.
In the investigator's opinion, any medical condition or psychiatric illness that could potentially be life threatening or affect their ability to complete the study visits according to this protocol.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00833001

Locations

Belgium
Sint Lodewijkstraat 78
Genk, Belgium
France
CHRU de Lille
Lille, France, 59037
Germany
St. Marien-Hospital
Vechta, Germany, D-49377
Kreiskrankenhaus
Hameln, Germany, 31785
Universitatsklinik Tubingen
Tubingen, Germany, 72076
Martin Luther University
Halle, Germany, 06097
DRT Krankenhaus
Chemnitz, Germany, 09034
Netherlands
Reinier de Graaf Gasthuis
Delft, Netherlands

Sponsors and Collaborators

Ethicon, Inc.

Investigators

Study Director:

David Robinson, MD

Ethicon, Inc.

More Information

Responsible Party:	Ethicon ( David Robinson MD/Medical Director )
Study ID Numbers:	300-07-006
Study First Received:	January 26, 2009
Last Updated:	January 29, 2009
ClinicalTrials.gov Identifier:	NCT00833001
Health Authority:	United States: Food and Drug Administration; Belgium: Federal Agency for Medicinal Products and Health Products; France: Afssaps - French Health Products Safety Agency; Germany: German Institute of Medical Documentation and Information; Netherlands: Dutch Health Care Inspectorate

Keywords provided by Ethicon, Inc.:

Anterior vaginal prolapse (medial, lateral,apical cystocele)
Posterior vaginal prolapse (rectocele and/or enterocele)
Vault prolapse (enterocele, uterine/vaginal vault prolapse)

Study placed in the following topic categories:

Pathological Conditions, Anatomical
Rectocele
Digestive System Diseases
Cystocele
Urologic Diseases
Gastrointestinal Diseases

Hernia
Urinary Bladder Diseases
Intestinal Diseases
Rectal Diseases
Prolapse
Rectal Prolapse

ClinicalTrials.gov processed this record on January 30, 2009